0403
Application of Collagen in Treatment of the Consequences of Injuries and Diseases of the Musculoskeletal System
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06331741/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–60 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 15 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (03.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Стадияместно-распространённая (III)
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 22 · невключение: 6
Критерии включения
- For ACL reconstruction groups:
- Type of damage (rupture of the anterior cruciate ligament (complete or partial);
- Availability of an informed consent form signed and dated by the patient.
- The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
- The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants.
- For collagen membrane of the first toe:
- The type of degenerative disease of the first metatarsophalangeal joint is Hallux rigidus of stage 3-4.
- Availability of an informed consent form signed and dated by the patient.
- The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
- The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants
- Non-inclusion criteria:
- Abuse of alcohol or narcotic substances (medicines).
- Any clinically significant or symptomatic vascular or neurological disease of the lower extremities.
- The presence of rheumatoid arthritis, parainfectious or infectious arthritis and the condition after the listed diseases, as well as the following diseases in the area of the damaged knee joint: septic arthritis, inflammatory joint disease, recurrent pseudopodagra, Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson-Konovalov disease, primary osteochondromatosis, hereditary diseases, mutation of collagen genes.
- Pregnancy and planned pregnancy (inability to perform MRI), lactation period.
- Obesity (body mass index > 30 kg/m2).
- Uncontrolled diabetes mellitus.
- Significant cardiovascular diseases currently or within 12 months prior to screening, including: chronic heart failure of class III or IV (according to the classification of the New York Cardiological Association), severe arrhythmia requiring treatment with antiarrhythmic drugs of classes Ia, Ib, Ic or III, unstable angina pectoris, myocardial infarction, heart and coronary surgery blood vessels, significant diseases of the heart valves, uncontrolled arterial hypertension with systolic blood pressure > 180 mmHg and diastolic blood pressure > 110 mmHg, pulmonary embolism or deep vein thrombosis;
- Significant thyroid dysfunction in the decompensation stage;
- Any uncontrolled concomitant somatic disease, including through a stable therapy regimen;
- Nephrotic syndrome, moderate to severe chronic renal failure, or significant kidney disease with creatinine levels > 1.5 mg/dl (132 mmol/l) in men and > 1.4 mg/dl (123 mmol/l) in women or glomerular filtration rate (GFR) < 60 ml/min;
- Current diagnosis of osteomyelitis and (or) infection with human immunodeficiency virus (HIV-1, HIV-2) and (or) hepatitis C virus (HCV) and (or) hepatitis B virus (HBV) and (or) syphilis. An increase in AST (aspartate transaminase), ALT (alanine transaminase) or alkaline phosphatase of serum ≥ 2.5 times from the upper limit of the norm; an increase in the level of total bilirubin ≥ 2 times from the upper limit of the norm;
Критерии невключения
- The patient's refusal to participate in the study;
- The development of an allergic reaction to the product;
- Loss of contact with the patient for further observation;
- The decision of the research physician to terminate the patient's participation in the study prematurely if, in the opinion of the researcher, the patient cannot continue further participation in the study for any reason.
- Inclusion in the study in violation of the inclusion/non-inclusion criteria.
- Significant protocol violations that may affect patient safety and/or the integrity of the study data (in consultation with the medical monitor).
Источник: ClinicalTrials.gov, NCT06331741 · запись обновлена в реестре 26 марта 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (6)
- The International Knee Documentation Committee score — 1,5 and 6 months postoperatively
- The Knee injury and Osteoarthritis Outcome Score — 1,5 and 6 months postoperatively
- Modified Lysholm scale — 1,5 and 12 months postoperatively
- Anterior Cruciate Ligament OsteoArthritis Score — 6 months postoperatively
- American Orthopaedic Foot and Ankle Society, Ankle-Hindfoot Score — 2, 4 and 8 weeks postoperatively
- 36-Item Short Form Survey — 2, 4 and 8 weeks postoperatively
Цель исследования
The purpose of the study:
Evaluation of the clinical efficacy and safety of the use of collagen matrix/membrane in the surgical treatment of the consequences of injuries and diseases of the musculoskeletal system (anterior cruciate ligament tears, rigid first toe) by using IKDC, KOOS, ACLOAS, VAS, AOFAS, SF-36 scales
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06331741 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.